These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 38549161)

  • 21. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
    Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
    Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting central nervous system pathologies with nanomedicines.
    Mizrahy S; Gutkin A; Decuzzi P; Peer D
    J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery.
    Banks WA
    Nat Rev Drug Discov; 2016 Apr; 15(4):275-92. PubMed ID: 26794270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted delivery of nano-therapeutics for major disorders of the central nervous system.
    Gao H; Pang Z; Jiang X
    Pharm Res; 2013 Oct; 30(10):2485-98. PubMed ID: 23797465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
    Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
    Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for delivering therapeutics across the blood-brain barrier.
    Terstappen GC; Meyer AH; Bell RD; Zhang W
    Nat Rev Drug Discov; 2021 May; 20(5):362-383. PubMed ID: 33649582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug delivery to the CNS and polymeric nanoparticulate carriers.
    Costantino L
    Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug delivery systems, CNS protection, and the blood brain barrier.
    Upadhyay RK
    Biomed Res Int; 2014; 2014():869269. PubMed ID: 25136634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders.
    Guo ZH; Khattak S; Rauf MA; Ansari MA; Alomary MN; Razak S; Yang CY; Wu DD; Ji XY
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
    Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
    Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanotechnology-based drug delivery for central nervous system disorders.
    Nguyen TT; Dung Nguyen TT; Vo TK; Tran NM; Nguyen MK; Van Vo T; Van Vo G
    Biomed Pharmacother; 2021 Nov; 143():112117. PubMed ID: 34479020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems.
    Patel V; Chavda V; Shah J
    Curr Neuropharmacol; 2021; 19(5):693-710. PubMed ID: 32851949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.